Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01487083 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Study in Schizophrenia
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
NCT01487083 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 282 participants.
The verdict
NCT01487083, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety of pomaglumetad methionil in participants with schizophrenia.
Interventions
- DRUG Pomaglumetad methionil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01487083
The ClinicalTrials.gov registry entry for NCT01487083 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pomaglumetad methionil is the first listed.
NCT01487083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01487083 about?
NCT01487083 is a clinical study titled "A Long-Term Study in Schizophrenia". The purpose of this study is to evaluate the long-term safety of pomaglumetad methionil in participants with schizophrenia.
What is the current status of trial NCT01487083?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2011-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01487083?
The interventions under investigation include: Pomaglumetad methionil (DRUG).
Who is sponsoring clinical trial NCT01487083?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.